
Semaglutide lowered MACE 41% within 6 months in SELECT, before major weight loss
A Medscape report on new SELECT data: semaglutide (Wegovy) was associated with a 41% lower risk of major adverse cardiovascular events within 6 months of starting, before substantial weight loss or reaching the full 2.4 mg dose. This suggests benefits beyond weight loss.

